by Instem Team | Mar 4, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
The earliest stages of drug research and development (R&D) generate massive volumes of scientific, operational, and compliance-critical data, often across disconnected tools, teams, and formats. That fragmentation slows decision-making, increases rework, and...
by Instem Team | Mar 3, 2026 | Company News
Instem is pleased to announce the completion of a significant refurbishment of its Stone, UK Headquarters. The revitalisation of the UK Headquarters is a strategic investment reflecting Instem’s commitment to excellence, innovation, and the creation of a modern...
by Instem Team | Mar 3, 2026 | Clinical, Quality System Management, Resources
Organizations today must deliver consistent, high‑quality products and services amid rising customer expectations and increasing regulatory demands. Traditional, reactive inspection methods are no longer enough—modern quality assurance (QA) requires proactive systems...
by Instem Team | Mar 2, 2026 | Clinical, Resources
The biostatistics industry is moving towards a language-agnostic modality. SAS has been the go-to programming language for biostatistics for decades. But R and other open-source languages are increasingly being used for their distinct capabilities and methodologies,...
by Instem Team | Feb 23, 2026 | In Silico & Data Insights, Leadscope, Regulatory Submission
My Thoughts on NAMs and the Future of Drug Development: Progress Demands Leadership Donna Robinson, Chief Commercial Officer, Instem New ideas, methods, and technologies appear all the time, especially in the biomedical space. While the hype is often well-earned, many...
